Physcomitrella patens is a widely recognized organism used as a model specimen in the field of synthetic glycobiology due to its unique properties such as haploid dominant life cycle, efficient homologous recombination, and production of complex glycans and glycoproteins. P. patens engineering in synthetic glycobiology involves a variety of technologies, prominent among which are gene editing tools and bioengineering techniques to modify metabolic pathways and generate specific glycoforms.

Physcomitrella patens Engineering Service at CD BioGlyco

As a professional biotechnology company, CD BioGlyco has an advanced GlycoChas™ Cells platform and focuses on providing Plant Chassis and various engineering services. Our P. patens engineering service incorporates the latest biotechnology and innovative methods to provide strong support for glycobiological research.

• Gene editing

  The CRISPR/Cas9 system is the most commonly used gene editing tool today and can be used to produce targeted gene knockout and specific targeted insertion of large transgenes in P. patens. CRISPR/Cas9 offers high precision and efficiency in systematically modifying genetic sequences.

  • Glycosyltransferase gene editing

    These genes are responsible for catalyzing the transfer reaction between glycan molecules to form glycan chains or glycosidic bonds. By editing these genes, the length, structure, or connection of glycan chains can be changed to produce glycans or glycoproteins with specific properties.

  • Glycan metabolism enzyme gene editing

    Glycan metabolism enzyme gene editing including key enzyme genes in glycolysis, gluconeogenesis, and other processes. By knocking out, down-regulating, or up-regulating the expression of these genes, the synthesis and decomposition rate of glycan can be regulated, affecting the production and accumulation of glycan.

• Metabolic pathway modification

  Synthetic glycobiology involves the modification of metabolic pathways to produce designed glycan structures. For example, by introducing mammalian genes into its genome, P. patens place these genes at specific sites in the P. patens genome through homologous recombination, thereby modifying the N-glycan biosynthetic pathway to generate complex N-glycans similar to those in humans.

  • Modification of glycan synthesis pathway

    • Adding new glycan synthesis pathways: By introducing exogenous genes or optimizing endogenous genes, new glycan synthesis pathways can be constructed to produce new glycans that do not exist in nature.

    • Optimizing existing glycan synthesis pathways: By knocking out or down-regulating genes in competing pathways, the production of by-products can be reduced, thereby increasing the production of target glycans.

  • Modification of glycoprotein synthesis pathway

    • Glycosylation modification: By editing glycosyltransferase genes, the structure and composition of the glycan chains on glycoproteins can be changed, thereby affecting the function and stability of glycoproteins.

    • Expansion of glycoprotein synthesis pathways: By introducing new glycosyltransferases or modifying enzymes, glycoprotein synthesis pathways can be expanded to produce glycoproteins with more complex glycan chain structures.

• Production of glycans and glycoproteins

  Through metabolic engineering, P. patens has been used to produce a variety of complex glycans and glycoproteins. This includes high mannose N-glycans, mixed N-glycans, and complex N-glycans.

Applications of P. patens Engineering

• It is possible to produce glycoproteins that are identical to those produced in humans through P. patens. This breakthrough in synthetic glycobiology opens up the potential for developing effective and safe glyco-drugs.
• P. patens engineering can be used in the development of vaccines, particularly glycoconjugate vaccines. P. patens system allows for the possibility of creating vaccines with defined and homogeneous glycan structures, leading to better immunogenicity and efficacy.
• P. patens engineering can be used to study disease mechanisms related to glycosylation. For instance, it can be used to understand the role of glycosylation in disease progression and to discover new targets for therapeutic interventions. This could pave the way for the development of efficient drugs for the treatment of glycosylation-related disorders such as certain types of cancer and genetic disorders.

CD BioGlyco focuses on providing advanced P. patens engineering services. We not only provide the P. patens chassis but also utilize this unique model organism to produce diversified glycan and glycoprotein products. Through precise gene editing and metabolic engineering, we produce glycans with specific structures and functions, such as monosaccharides like glucose and fructose, as well as glycoproteins with unique glycan chain structures. We welcome clients to contact us to discuss cooperation opportunities.

• Nicotiana benthamiana Engineering Service
• Nicotiana tabacum Engineering Service
• Arabidopsis thaliana Engineering Service
• Lemna minor Engineering Service
• Oryza sativa Engineering Service
• Medicago sativa Engineering Service